Gozal D, Hengy C, Fadat G
Israel Embassy, Yaoundé, Cameroon.
Antimicrob Agents Chemother. 1991 Feb;35(2):373-6. doi: 10.1128/AAC.35.2.373.
One hundred thirty nonimmune subjects living in Yaoundé, Cameroon, completed an 18-month prospective study on the efficacy and safety of weekly chloroquine and daily proguanil (chloroguanide) (Ch-P) in malaria prevention. A total of 9 of 78 Ch-P-treated subjects and 26 of 52 subjects who received no prophylaxis contracted Plasmodium falciparum infection during this period (P less than 0.00005). These two groups were comparable for demographic parameters and degree of exposure. Clinical manifestations were of similar severities in the two groups, but parasite counts were significantly higher in the subjects who received no prophylaxis (P less than 0.00005). Side effects of prophylaxis were frequent (31%), minor, and related to chloroquine, and they usually resolved within 4 to 6 weeks. Prolonged administration of Ch-P is safe and effectively prevents P. falciparum malaria in an endemic area with a high prevalence of chloroquine resistance.
130名来自喀麦隆雅温得的非免疫受试者完成了一项为期18个月的前瞻性研究，该研究旨在探讨每周服用氯喹和每日服用氯胍（氯胍）（Ch-P）预防疟疾的有效性和安全性。在此期间，78名接受Ch-P治疗的受试者中有9人感染了恶性疟原虫，而52名未接受任何预防措施的受试者中有26人感染（P<0.00005）。这两组在人口统计学参数和暴露程度方面具有可比性。两组的临床表现严重程度相似，但未接受预防措施的受试者的寄生虫计数明显更高（P<0.00005）。预防措施的副作用很常见（31%），程度较轻，且与氯喹有关，通常在4至6周内消失。在氯喹耐药率很高的流行地区，长期服用Ch-P可安全有效地预防恶性疟原虫疟疾。
